Charles River Laboratories International, Inc. has announced the successful completion of its acquisition of PathoQuest, a specialist in next gen...
The demand for nucleic acid therapeutics (NATs) is rapidly altering the therapeutic landscape across a wide range of diseases. Recent industry data highlig...
Oncodesign Services has extended its collaboration with GIP ARRONAX to secure access to astatine-211 (At-211) as well as other radionuclides used in targ...
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its new ...
New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune response...
MasterControl, a leading provider of quality and manufacturing software solutions for life sciences and regulated industries, has a...
PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, and Covaris, a PerkinElmer company and leader in sample...
Expanded treatment in community settings will reduce patient burden Option to redose patients granted in both Ntrust-1 and Ntrust-2 studies Rheumatoi...
Ardena, a specialist CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces that its new state-of –the-art ...
Dataset will drive crucial insights to accelerate scientific discovery and ultimately improve pediatric patient care. Illumina (NASDAQ: ILMN) and...
Strategic partnership enables upskilling of Novo Nordisk’s workforce and places the company at the forefront of AI transformation in healthcare ...
The Elecsys NfL blood test detects neuroaxonal damage associated with neuroinflammation in adults diagnosed with relapsing remitting multiple sclerosis...
Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of heavily pre-...
OncoC4 Inc., a late clinical stage biopharmaceutical company, announced first participant's dosing following the clearance of the Investigational New Dru...
© 2026 Biopharma Boardroom. All Rights Reserved.
